Pfizer Inc (PFE) 30.58 $PFE
Market Maker Surveillance Report. GM, KO, PFE, BAC, MS, VZ, Bullishly Biased Price Friction For Thursday, September 18th 2014
M2 - 1 hr 26 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. General Motors Co (NYSE:GM), The Coca-Cola Co (NYSE:KO), Pfizer Inc (NYSE
FE), BANK OF AMERICA CORPORATION (NYSE:BAC), Morgan Stanley (NYSE:MS), Verizon Communications Inc (NYSE:VZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Most active New York Stock Exchange-traded stocks
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Midday Glance: Pharmaceuticals companies
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
How Will Auxilium Pharmaceuticals (AUXL) Stock React to FDA's Stendra Approval?
at The Street - Thu Sep 18, 9:35AM CDT
Shares of Auxilium Pharmaceuticals (AUXL) were flat in morning trading Thursday despite the FDA's approval of the company's erectile dysfunction drug Stendra.
Why VIVUS (VVUS) Stock Is Up Today
at The Street - Thu Sep 18, 9:17AM CDT
Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.
3 Huge Stocks on Traders' Radars: SHLD, PFE, GILD
at The Street - Wed Sep 17, 1:25PM CDT
Here's how to trade some of the most active stocks on the market today.
Early Glance: Pharmaceuticals companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Stock Market News for September 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 9:10AM CDT
Benchmarks settled in the green on Tuesday following a report from Wall Street Journal stating Fed might not raise interest rate sooner-than-expected
Pfizer (PFE) Breaks Through Resistance at $30.20
Comtex SmarTrend(R) - Wed Sep 17, 8:59AM CDT
Pfizer (NYSE FE) has opened bullishly above the pivot of $29.97 today and has reached the first level of resistance at $30.20. Investors may be interested in a cross of the next upside pivot targets of $30.34 and $30.71.
MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease
Marketwire - Tue Sep 16, 8:07AM CDT
MedGenesis Therapeutix Inc. ("MedGenesis"
, a privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, announced today that it has entered into an agreement with Pfizer Inc. ("Pfizer" , granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.
Market Maker Surveillance Report. GM, KO, PFE, BAC, MS, VZ, Bullishly Biased Price Friction For Thursday, September 18th 2014
M2 - 1 hr 26 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4944 companies with "abnormal" market making, 2520 companies with positive Friction Factors and 2350 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. General Motors Co (NYSE:GM), The Coca-Cola Co (NYSE:KO), Pfizer Inc (NYSE
FE), BANK OF AMERICA CORPORATION (NYSE:BAC), Morgan Stanley (NYSE:MS), Verizon Communications Inc (NYSE:VZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . Most active New York Stock Exchange-traded stocks
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
Merck Enters into Licensing Agreement with Sun Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:55PM CDT
Merck & Co., Inc., (MRK) entered into a worldwide licensing agreement with Sun Pharmaceutical Industries Ltd.
Midday Glance: Pharmaceuticals companies
AP - Thu Sep 18, 12:18PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
FDA OKs faster-acting label for ED drug Stendra
By The Associated Press - AP - Thu Sep 18, 11:21AM CDT
Federal regulators have approved a new label for Vivus' impotence drug, stating that it becomes effective in half the time that the previous label had stated.
How Will Auxilium Pharmaceuticals (AUXL) Stock React to FDA's Stendra Approval?
at The Street - Thu Sep 18, 9:35AM CDT
Shares of Auxilium Pharmaceuticals (AUXL) were flat in morning trading Thursday despite the FDA's approval of the company's erectile dysfunction drug Stendra.
Why VIVUS (VVUS) Stock Is Up Today
at The Street - Thu Sep 18, 9:17AM CDT
Shares of VIVUS (VVUS) were up in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.
3 Huge Stocks on Traders' Radars: SHLD, PFE, GILD
at The Street - Wed Sep 17, 1:25PM CDT
Here's how to trade some of the most active stocks on the market today.
Early Glance: Pharmaceuticals companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Stock Market News for September 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 9:10AM CDT
Benchmarks settled in the green on Tuesday following a report from Wall Street Journal stating Fed might not raise interest rate sooner-than-expected
Pfizer (PFE) Breaks Through Resistance at $30.20
Comtex SmarTrend(R) - Wed Sep 17, 8:59AM CDT
Pfizer (NYSE
FE) has opened bullishly above the pivot of $29.97 today and has reached the first level of resistance at $30.20. Investors may be interested in a cross of the next upside pivot targets of $30.34 and $30.71. MedGenesis Enters Into Agreement with Pfizer Inc. for Potential Treatments for Parkinson's Disease
Marketwire - Tue Sep 16, 8:07AM CDT
MedGenesis Therapeutix Inc. ("MedGenesis"
, a privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, announced today that it has entered into an agreement with Pfizer Inc. ("Pfizer" , granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease. 
